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Background: In this study, we evaluated the anti-inflammatory effect of PM014 on cigarette smoke induced lung
disease in the murine animal model of chronic obstructive pulmonary disease (COPD).
Methods: Mice were exposed to cigarette smoke (CS) for 2 weeks to induce COPD-like lung inflammation. Two
hours prior to cigarette smoke exposure, the treatment group was administered PM014 via an oral injection. To
investigate the effects of PM014, we assessed PM014 functions in vivo, including immune cell infiltration, cytokine
profiles in bronchoalveolar lavage (BAL) fluid and histopathological changes in the lung. The efficacy of PM014 was
compared with that of the recently developed anti-COPD drug, roflumilast.
Results: PM014 substantially inhibited immune cell infiltration (neutrophils, macrophages, and lymphocytes) into
the airway. In addition, IL-6, TNF-α and MCP-1 were decreased in the BAL fluid of PM014-treated mice compared to
cigarette smoke stimulated mice. These changes were more prominent than roflumilast treated mice. The
expression of PAS-positive cells in the bronchial layer was also significantly reduced in both PM014 and roflumilast
treated mice.
Conclusions: These data suggest that PM014 exerts strong therapeutic effects against CS induced, COPD-like lung
inflammation. Therefore, this herbal medicine may represent a novel therapeutic agent for lung inflammation in
general, as well as a specific agent for COPD treatment.
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Chronic obstructive pulmonary disease (COPD) is a com-
mon public health concern worldwide, and the incidence
of COPD is increasing globally [1,2]. COPD is character-
ized by progressive and irreversible airway obstruction [3].
Chronic inflammation contributes to a decline in pulmon-
ary function associated with chronic bronchitis, mucus
hypersecretion, and emphysema via the release of pro-
inflammatory mediators, reactive oxygen species, and* Correspondence: hbae@khu.ac.kr
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reproduction in any medium, provided the ortissue degradation enzymes [4]. Subsequently, these pul-
monary changes result in abnormalities in gas exchange at
the pulmonary level and respiratory failure [5]. The path-
ology of COPD differs markedly from that of asthma
[6-8]. In larger airways, there is evidence of neutrophilic
rather than eosinophilic inflammation, as indicated by an
increased number of neutrophils in BAL fluid. Current
conventional treatment is aimed at relieving symptoms,
preventing recurrent exacerbation, preserving optimal
lung function and enhancing overall quality of life [9]. Al-
though many drugs are used to treat COPD, the adverse
effects associated with several classes of drugs, such as ste-
roids, have increased the need for alternative treatments,
such as herbal medicines [10,11].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Composition and amount of PM014
Herb Pharmaceutical name Amount (g)
Suckjihwag Rehmannia Radix Preparata 600
Mockdanpi Moutan Cortex 300
Omija Schisandrae Fructus 300
Chunmundong Asparagi Tuber 300
Hengin Armeniacae Semen 225
Hwangkum Scutellariae Radix 225
Baekbukuen Stemomae Radix 150
Total 2,100 g
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essential to determine whether novel anti-inflammatory
agents can halt or slow the decline in lung function
that occurs in response to this disease when selecting
candidate drugs. Several studies have demonstrated that
compounds derived from plants have anti-inflammatory
or immune-modulating properties [12], and several
herbal medicines, including Panax ginseng and Salvia
miltiorrhiza, have been used for COPD treatment [13].
PM014 is modified from Chung-Sang-Bo-Ha-Tang
(CSBHT). The Chung-Sang-Bo-Ha-Tang (CSBHT) has
been especially used to treat chronic pulmonary diseases
in Korea for centuries [14]. Previously, we developed the
formulation of PM014 based on the series of in vitro
and in vivo screening efforts. The results showed that
PM014 possessed potent anti-inflammatory effects in
both lipopolysaccharide (LPS)-induced and elastase/LPS
induced acute lung inflammation murine models [15].
However, the previous study only suggested the prophy-
lactic effects of PM014 in lung injury. In addition, the
lung inflammation inducer did not reflect the actual en-
vironment. To overcome these limitations, we evaluated
PM014 to determine if it had therapeutic effects on lung
inflammation in a mouse model of CS-induced lung
neutrophilia that mimicked a COPD-like lung injury
[16]. CS-associated chronic obstructive pulmonary dis-
ease (COPD) is characterized by inflammation, changes
affecting small airways and the development of emphy-
sema [17]. The main pathological characteristics of CS-
associated COPD are inflammation along the bronchus
and bronchioles, fibrosis, smooth muscle hypertrophy,
goblet cell hyperplasia, small airway and vascular remod-
eling, and development of centrilobular emphysema
[18]. In addition, CS is a very strong environmental risk
factor that is linked to rheumatoid arthritis (RA) [19,20]
and other autoimmune diseases [21-23]. CS is a toxic
and carcinogenic mixture of more than 5,000 chemicals
[24]. Of these chemicals, approximately 400 have been
quantified; at least 200 are toxic to humans and/or ex-
perimental animals; and over 50 have been identified as
known, probable, or possible human carcinogens [25].
Mainstream smoke typically contains large amounts of
bacterial and fungal compounds, such as endotoxins
(lipopolysaccharide, LPS, in the outer membrane of
Gram-negative bacteria) and ergosterol (a specific fungal
membrane lipid) [26].
Roflumilast is indicated as a treatment to reduce the
risk of COPD exacerbations in patients with severe
COPD associated with chronic bronchitis and a history
of exacerbation [27]. Roflumilast is a lipophilic, highly
permeable molecule that exhibits rapid and nearly
complete absorption after oral administration [28].
In the present study, we evaluated the anti-inflammatory
effects of PM014 on CS-induced lung inflammation in miceand elucidated the possible mechanism by which PM014
suppresses CS-induced lung inflammation.
Methods
Reagent
PM014, contains 7 species of medicinal plants, was pur-
chased from Kyung Hee Herb Pharm (Seoul, South
Korea) and processed in Hanlim Pharm Co. LTD (Seoul,
South Korea). Every herb of PM014 was cut and mixed
amount of 2,100 g as the ratio indicated in Table 1. It
was extracted with purified water (2,100 mL) using a re-
flux for 3 hours at 90 ~ 100°C, and then filtered by using
25 μm sieve. Supernatant was concentrated at 60°C
under vacuum using an evaporative system. Extracts and
260 g of dry corn starch were mixed, and then vacuum
dried at 60°C. The PM014 extract powder was dissolved
in PBS. The amount of standard materials in the final
extracts (1 g) of PM014 were; Paeoniflorin > 0.43 mg,
Schizandrin > 0.12 mg, Baicalin > 7.26 mg, and Amyg-
dalin > 2.48 mg. Roflumilast (Santa Cruz Biotechnology,
Inc. Delaware Avenue, CA, U.S.A.), which was used as a
positive control, was also dissolved in PBS.
Animal and maintenance conditions
In this study, female Balb/c (6–7 weeks of age) mice (n=
5–6 per group) were whole-body exposed to room fresh
air or cigarette smoke of 6 cigarettes (Reference
Cigarette to 3R4F without a filter, University of Ken-
tucky, Lexington, KY, U.S.A.) a day for 2 weeks, one
cigarette every 5 min for total exposure time 30 min
(cigarette was completely burned in the first 1 min). The
mice were exposed to cigarettes in smoke chamber
(1.54 m × 0.52 m × 0.22 m, Live Cell Instrument, Seoul,
South Korea) from on days 0 to 1, 4 to 8, and 11 to 13
as outlined in overall exposure procedures (Figure 1).
For treatment, each group of mice were orally adminis-
tered 2 hr before cigarette smoke with CS group,
rolfulmilast (ROF) group, as a positive control group,
and mixtures of PM014 (50, 100, 200 mg/kg wt) groups
for the duration of the study from day 5 to 13. The con-
trol (CON) group (age and sex-matched Balb/c mice)
Figure 1 Schematic diagram of the experimental protocol. Specific pathogen-free, 7-week-old, female balb/c mice were administered
cigarettes on days 0 to 1, 4 to 8, and 11 to 13, as outlined above in the general exposure procedures. The mice were sacrificed on day 14.
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hours after the last exposure, mice were sacrificed and
collect BAL fluid and lung specimen. These experiments
were performed twice. The experimental procedure was
approved by the Institutional Animal Care and Use
Board of Kyung Hee University (KHUASP (SE)-12-015).
Analysis of BAL cells
The mice were sacrificed via cervical vertebral disloca-
tion. PBS (phosphate buffered saline) was slowly infused
into the lungs and withdrawn via a cannula inserted into
the trachea. The cell numbers were counted using
a hemocytometer, and differential cell counts were
performed on slides prepared by cytocentrifugation at
250 rpm for 3 min and Diff-Quick staining. Approxi-
mately 500 cells were counted. BAL fluid was then
centrifuged, and the supernatants were kept at −80°C.
ELISA measurements of IL-6 and TNF-α and MCP-1 in
bronchoalveolar lavage fluids
Protein concentrations were determined using a BCA kit
(Pierce Biotechnology Inc., Rockford, IL, U.S.A.). IL-6,
TNF-α, and MCP-1 concentrations were measured with a
quantitative sandwich enzyme-linked immunoassay kit
(BD, San Diego, CA, U.S.A.). A 96-well microtiter plate was
incubated overnight at 4°C with anti-rat IL-6,TNF-α and
MCP-1 monoclonal antibody in coating buffer, washed
with PBS containing 0.05% tween 20 (Sigma, St. Louis,
MO, U.S.A.) and blocked with 5% FBS in PBS for 1 hr at
room temperature. Subsequently, the BAL fluid (100 μl)
was incubated for 2 hr at room temperature. Then, second-
ary peroxidase-labeled biotinylated anti-rat IL-6, TNF-α,
and MCP-1 monoclonal antibody was incubated in 5% FBS
in PBS for 1 hr. Finally, the plates were treated with TMB
substrate solution for 30 min, and the reaction was stopped
by adding TMB stop solution (BD, San Diego, CA, U.S.A.).
Optical density was measured at 450 nm in a microplate
reader (SOFT max PRO software, Sunnyvale, CA, U.S.A.).Preparation of lung tissues and histology
The lung tissues were removed from the mice, and the
right lower lobes were removed for histological analysis.
Four percent paraformaldehyde fixing solution was infused
into the lungs. The specimens were dehydrated and em-
bedded in paraffin. For histological examination, 4 μm sec-
tions of embedded tissue were cut on a rotary microtome,
placed on glass slides, deparaffinized, and stained sequen-
tially with hematoxylin and eosin (H&E). The severity of
peribronchial inflammation was graded semi-quantitatively
as previously described [29]. Hyperplasia of the goblet cells
within the bronchial epithelium was assessed by counting
cells in periodic acid Schiff (PAS)-stained sections. Slides
were mounted with Canada balsam (Showa Chemical Co.
Ltd., Tokyo, Japan). PAS-positive cells in the epithelium
and total epithelial cells were counted, and the percentage
of PAS-positive cells was calculated. For quantitating air
space in lung, the sections with the maximum parenchyma
cross-sections were selected for morphometric analysis
using a digitized image tool [30]. Micrographs were
obtained using Image Pro-Plus 5.1 software (Media Cyber-
netics, Inc. Silver Spring, MD, U.S.A.).
Statistical analysis
Data are presented as the means ± S.E.M. Data analysis
was conducted using Graphpad Prism software (version
4, San Diego, CA, U.S.A.). The differences between study
groups were determined by one-way ANOVA and the
Newman-Keuls multiple comparison test. P < 0.05 was
considered to be statistically significant.
Results
The effects of PM014 on total and inflammatory cells
levels in BAL fluid
We made an experiment with various doses of PM014
(0.1, 1, 10 and 100 mg/kg wt) to test its anti-
inflammatory effect on CS-induced COPD. As a result,
PM014 did not show significant effect on concentration
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nificantly decreased number of total leukocytes, neutro-
phils, macrophages and lymphocytes in BAL fluid
compared with CS-exposure group (Table 2). To find
the optimal dosage of PM014, we conducted separate
experiment with three different dosages of PM014
around 100 mg/kg (50, 100 and 200 mg/kg wt). Cigarette
smoke exposed (CS) group showed significantly in-
creased numbers of neutrophils, lymphocytes, macro-
phages and total cells compared with fresh air exposed
(CON) group. Treatment groups with PM014 (50, 100,
200 mg/kg wt) or roflumilast (ROF) group exhibited re-
markably decreased numbers of total cells, neutrophils,
lymphocytes and macrophages in BAL fluid compared
with the CS-exposure group (Figure 2).
The effect of PM014 on IL-6, TNF-α and MCP-1 in BAL
fluids by CS-induced mice
Pro-inflammatory cytokines (TNF-α, IL-6) contribute to
cigarette smoke induced COPD. MCP-1 is potent
chemoattractant of monocytes and acts on the recruit-
ment of macrophages in COPD. To evaluate the
anti-inflammatory effects of PM014, the secretion of
pro-inflammatory cytokines and CC chemokine in BAL
fluid were measured. Secretion of TNF-α, IL-6 and
MCP-1 were significantly elevated in CS group when
compared with the CON group. Positive treatment with
ROF group showed markedly reduced levels of IL-6 and
TNF-α than CS group. However, ROF group failed to in-
hibit MCP-1 releasing. The PM014 (100, 200 mg/kg wt)
groups also showed reduced level of IL-6 and TNF-α in
BAL fluid than CS group. Decrement of MCP-1 was
only observed 100 mg/kg treatment of PM014 compared
with CS group. In addition, PM014 (100 mg/kg wt)
group was similar to the CON group on IL-6, TNF-α
and MCP-1. However, treatment with PM014 (50 mg/kg
wt) data not shown significantly decreased of IL-6, TNF-
α and MCP-1 levels than CS group (Figure 3).
The Effect of PM014 on histologic lung damage
To determine if PM014 exerted an effect on CS-induced
lung damage, lung sections were stained with hematoxylin
and eosin (H&E). The results of histological examinationTable 2 Bronchoalveolar analysis
(× 104/ml) CON CS ROF
Total cells 2.80 ± 1.10 12.00 ± 1.79*** 6.20 ± 1.10#
Neutrophils 0.00 ± 0.00 0.31 ± 0.02*** 0.08 ± 0.03##
Macrophages 2.78 ± 1.08 12.30 ± 1.21*** 6.37 ± 1.20##
Lymphocytes 0.01 ± 0.02 0.17 ± 0.03*** 0.09 ± 0.04#
Data are shown as mean ± S.E.M. CON control group, CS cigarette smoke exposed
by one-way ANOVA followed by Newman-Keuls Multiple Comparison test (***p < 0of lung tissue paralleled the cell number in the BAL
fluid. Marked influxes of inflammatory cells into the
peribronchial layer and intraluminal areas were detected
in the lung sections of CS group. Additionally, PM014
treatment led to a marked reduction in the infiltration of
inflammatory cells within the lung in CS group that was
similar to the results observed in ROF group. These re-
sults demonstrated that treatment with PM014 inhibited
CS-induced inflammation in lung tissue in a fashion simi-
lar to ROF group (Figure 4A, 4B). In addition, CS expos-
ure in mice led to airspace enlargement. Performing
qrofuantitative analysis of alveolar airspace enlargement,
CS group showed alveolar destruction, which resulted in
enlarged air spaces, indicating emphysematous change
than in the that treatment with PM014 groups. In con-
trast, mice treated with PM014 showed less alveolar dam-
age (Figure 4C).
The effect of PM014 on goblet cell hyperplasia in
bronchial airways
To evaluate the effect of treatment with PM014 in goblet
cell hyperplasia, lung tissues were stained using periodic
acid-Schiff (PAS) (Figure 5A). Consistent with previous
results, PAS-positive mucus-counting goblet cells around
the bronchial airway epithelium of were more abundantly
detected in the CS group than CON group. On the other
hand, PM014 treatment considerably decreased PAS-
positive goblet cells around the bronchial airway epithe-
lium (Figure 5B). Taken together, these findings indicate
that treatment with PM014 has a powerful therapeutic
effect on CS-induced lung inflammation.
Discussion
Inflammation in COPD is complicated, with inflamma-
tory and structural cells that release various mediators,
including mediators such as LTB4, IL-8 and GCP-2,
which were chemoattractant for neutrophil and chemokines
such as MCP-1 and MIP-1α, which attract macrophage
[31]. An accumulation of inflammatory cells such as
neutrophils, macrophages, dendritic cells CD+8T lym-
phocytes is seen [32]. In our study, the infiltration of
inflammatory cells in BAL fluid and in the lung paren-
chyma was observed following exposure to cigarettes.PM014 PM014 PM014 PM014
0.1 mg/kg 1 mg/kg 10 mg/kg 100 mg/kg
11.60 ± 2.97 11.20 ± 3.90 10.40 ± 4.78 5.67 ± 2.66##
0.28 ± 0.11 0.26 ± 0.12 0.19 ± 0.05 0.06 ± 0.07###
11.20 ± 2.85 11.17 ± 4.41 8.24 ± 2.40 4.70 ± 2.29###
0.12 ± 0.05 0.13 ± 0.04 0.11 ± 0.06 0.03 ± 0.02###
group, and ROF roflumilast treated group. Statistical analyses were conducted
.001 vs. CON, ###p < 0.001, ##p < 0.01, #p < 0.05 vs. CS; n = 4–6).
Figure 2 Cellular profiles in BAL fluid and microscopic findings of the intrapulmonary bronchi. After sacrificing the mice, PBS buffer was
slowly infused into the lungs and withdrawn via a cannula inserted into the trachea. The cell numbers were counted using a hemacytometer,
and differential cell counts were performed on slides prepared by cytocentrifugation at 250 rpm for 3 min and Diff-Quick staining. A) Count of
total cell number, B) Count of neutrophils, C) Count of macrophages, D) Count of lymphocytes. Data are shown as mean ± S.E.M. Statistical
analyses were conducted by one-way ANOVA followed by Newman-Keuls Multiple Comparison test (***p < 0.001, **p < 0.01 vs. CON,
###p < 0.001, ##p < 0.01, #p < 0.05 vs. CS; n = 5–6).
Figure 3 The effect of PM014 on IL-6, TNF-α and MCP-1 in BAL fluid. BAL fluids were collected as described in Figure 2. A) Level of IL-6,
B) Level of TNF-α, C) Level of MCP-1 concentrations were measured with a quantitative sandwich enzyme-linked immunoassay. Data are shown
as mean ± S.E.M. Statistical analyses were conducted by one-way ANOVA followed by Newman-Keuls Multiple Comparison test (***p < 0.001 vs.
CON, ###p < 0.001, #p < 0.05 vs. CS; n = 5–6).
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Figure 4 The effect of PM014 morphology changes in CS exposure mice. A) Right lower lobes of mice were dissected and stained with
hematoxylin and eosin. B) The degree of inflammation was quantified using a semi-quantitative scale. C) Air space was calculated by Image
Pro-Plus 5.1 software as described in the Materials and Methods section. Data are shown as mean ± S.E.M. Statistical analyses were conducted
by one-way ANOVA followed by Newman-Keuls Multiple Comparison test (***p < 0.001 vs. CON, ##p < 0.01 vs. CS).
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damage in COPD through the release of a number of
mediators, including proteases, such as elastases and
matrix metalloproteinase, and oxidants and toxic pep-
tides, such as defensins [33].Concomitant with the influx of neutrophils, increased
levels of the pro-inflammatory cytokines, TNF-α and
IL-6 were observed in the BAL fluid by Cigarette smoke
(CS) exposure induce mice model. In addition, the ex-
pression of inflammation-related cytokines, such as IL-6
Figure 5 The effect of PM014 on goblet cell number. The right lower lobes of mice were dissected and stained with periodic acid Schiff. A)
The arrow indicates the PAS-positive cells. B) Periodic acid Schiff (PAS)-positive mucosal goblet cells around the bronchial airway were counted
and are depicted as the percentage of goblet cells, as described in the Materials and Methods section. Data are shown as mean ± S.E.M.
Statistical analyses were conducted by one-way ANOVA followed by Newman-Keuls Multiple Comparison test (***p < 0.001vs. CON,
###p < 0.001 vs. CS).
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in the airway. Also, CS-induced goblet cell hyperplasia is
associated with the development of bronchitis which
is related to COPD, which depends on the degree of
epithelial inflammation [34]. Goblet cell hyperplasia is
one of the morphogic changes in lung epithelium. In
addition to that, there are various epithelial changes in-
cluding submucosal gland hypertrophy associated with
loss of ciliated epithelial cell number, leading to reduced
mucociliary clearance, and mucus plug formation [35].
Cigarette smoke can contribute to the development of
many human diseases, such as cardiovascular disease,
lung cancer, asthma, and chronic obstructive pulmonary
disease. Thousands of compounds are present in CS,
including a large number of reactive oxygen species
that can cause DNA damage and lead to the activation
of poly (ADP-ribose) polymerase (PARP) enzyme [36].
Other components of CS, such as nicotine and acro-
lein, have also been shown to exert direct genotoxic
effects [37,38].In our study, the infiltration of inflammatory cells in
BAL fluid was observed after CS exposure. Exposure to
CS induced several pathological changes, such as inflam-
matory cell accumulation in the lung parenchyma,
hyperplasia of goblet cells, hypersecretion of mucus, al-
veoli enlargement, and increases in collagenic and elastic
structures in the alveolus. The pathological changes ob-
served in this study were very similar to the clinical fea-
tures of COPD patients [33]. In this CS exposure model,
the herbal mixture PM014 showed consistent efficacy
comparable with that of the commercially available anti-
COPD drug, roflumilast [39].
Herbal mixtures are widely used as traditional medi-
cines to treat many different types of disease [40,41]. In
Korean traditional medicine, herbs are used as mixtures
rather than as one herb by itself. PM014 is modified
from Chung-Sang-Bo-Ha-Tang (CSBHT). The Chung-
Sang-Bo-Ha-Tang (CSBHT) has been especially used to
treat chronic pulmonary diseases in Korea for centuries.
However, CSBHT contains 18 species of medicinal
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mula [14]. Therefore, CSBHT was modified to PM014,
which contains 7 species of medicinal plants. Previously,
we initially compared the effects of each herb and the
PM014 herbal mixture in an acute LPS-induced lung
injury model [15]. Stemona sessilifolia, S. japonica and
S. tuberose are the three original sources of Stemonae
Radix specified in Chinese Pharmacopoeia (CP) and have
been traditionally used as antitussive and insecticidal
remedies [42]. Asparagus cochinchinensis is used for
treating lung- and spleen-related diseases [43]. A bio-
active flavonoid extracted from the root of Scutellaria
baicalensis has anti-inflammatory and anti-angiogenic
activities [44]. Schisandra chinensis fruit especially allevi-
ates cough and satisfies thirst. In modern pharmaceutical
studies, Schisandra chinensis fruit has been reported to
reduce hepatotoxicity [45-50]. The root of Rehmannia
glutinosa (RR) is commonly used to reduce inflamma-
tion [51]. The root cortex of Paeonia suffruticosa An-
drews (PSA), also known as Moutan Cortex, is known to
have anti-allergic and anti-inflammatory properties [52].
Individual herb extracts in PM014 also attenuated the
immune cell influx; however, treatment with the herbal
mixture PM014 resulted in less recruitment of all im-
mune cells toward the lungs than the individual herbal
treatments [15]. Therefore, it is assumed that using a
mixture of 7 medicinal herbs is more effective with
regard to synergism than using each of the 7 herbs
separately. These results may suggest that PM014 is a
powerful therapeutic agent, which reduces chronic accu-
mulation of inflammatory cells induced by CS. In this
study, PM014 (50, 100, 200 mg/kg wt) markedly reduced
inflammatory cells in BAL fluid. Furthermore, when we
compared the histological findings, PM014 (100 mg/kg wt)
significantly reduced the numbers of lymphocytes, neu-
trophils, infiltrating macrophage and the level of goblet
cell metaplasia. Epithelial basement membrane thicken-
ing and inflammation of the bronchiole also were re-
markably inhibited. PM014 (100 mg/kg wt) also, markedly
reduced levels of TNF-α, IL-6 and MCP-1 than CS group.
However, PM014 (50 mg/kg wt) did not show significant
effect than PM014 (100, 200 mg/kg wt) in TNF-α, IL-6,
and MCP-1 production.
TNF-α, an early pro-inflammatory cytokine, is believed
to trigger the activation of other pro-inflammatory cyto-
kines, such as IL-6 and IL-8 [53]. TNF-α also activates
nuclear factor-κB, which increases IL-8 gene transcrip-
tion, thereby inducing the release of IL-8 from the airway
epithelium and neutrophils. IL-8, a CXC chemokine, is a
neutrophil chemoattractant and activator [33]. MCP-1 a
monocyte selective chemokine which attracts monocytes
to lung is increased in lung COPD patients [54]. Macro-
phages mediate inflammation in COPD through the re-
lease of chemokines that attract neutrophils, monocytesand T-cells and releases serine proteases like matrix
metalloproteinase (MMP-9) [55].
In our study, PM014 downregulated pro-inflammatory
cytokine production in both acute and chronic lung
inflammation. Therefore, treatment with PM014 may act
steadily on downstream events, including the influx of
inflammatory cells and the levels of mediators aggravat-
ing the inflammatory response. In addition, histopatho-
logical data implied that PM014 administration inhibited
the progression of airspace enlargement and goblet
cell hyperplasia. Theses result also demonstrated that
PM014 could be sufficient to structural changes of lung,
typical of COPD.
Conclusions
The results of this study provide evidence that treatment
with PM014 exerts therapeutic effects against smoking-
induced lung inflammation in mice. The remarkable
anti-inflammatory effects exerted by PM014 suggest that
it has the potential to be used in the treatment of COPD
patients. However, further study to elucidate the mecha-
nisms underlying the action of PM014 should be
conducted to aid in the discovery of new therapeutic
agents for COPD treatment.
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